Risk of severe COVID-19 in unvaccinated patients during the period from wild-type to Omicron variant: real-world evidence from Japan

被引:0
|
作者
Tomioka, Kimiko [1 ,2 ]
Uno, Kenji [2 ,3 ]
Yamada, Masahiro [2 ]
机构
[1] Nara Med Univ, Nara Prefectural Hlth Res Ctr, Nara, Japan
[2] Chuwa Publ Hlth Ctr Nara Prefectural Govt, Nara, Japan
[3] Minami Nara Gen Med Ctr, Dept Infect Dis, Nara, Japan
关键词
COVID-19; SARS-CoV-2; Severe outcomes; Wild-type; Omicron; Community-based study; Japan; SARS-COV-2; INFECTION;
D O I
10.1265/ehpm.23-00274
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Many studies have reported that the Omicron variant is less pathogenic than the Delta variant and the wild-type. Epidemiological evidence regarding the risk of severe COVID-19 from the wild-type to the Omicron variant has been lacking. Methods Study participants were COVID-19 patients aged 18 and older without previous COVID-19 infection who were notified to the Nara Prefecture Chuwa Public Health Center from January 2020 to March 2023, during the periods from the wild-type to the Omicron variant. The outcome variable was severe COVID-19 (i.e., ICU admission or COVID-19-related death). The explanatory variable was SARS-CoV-2 variant type or the number of COVID-19 vaccinations. Covariates included gender, age, risk factors for aggravation, and the number of general hospital beds per population. The generalized estimating equations of negative binomial regression models were used to estimate the adjusted incidence proportion (AIP) with 95% confidence interval (CI) for severe COVID-19. Results Among 77,044 patients included in the analysis, 14,556 (18.9%) were unvaccinated and 520 (0.7%) developed severe COVID-19. Among unvaccinated patients, the risk of severe COVID-19 increased in the Alpha/Delta variants and decreased in the Omicron variant compared to the wild-type (AIP [95% CI] was 1.55 [1.06-2.27] in Alpha/Delta and 0.25 [0.15-0.40] in Omicron), but differed by age. Especially in patients aged >= 80, there was no significant difference in the risk of severe COVID-19 between the wild-type and the Omicron variant (AIP [95% CI] = 0.59 [0.27-1.29]). Regarding the preventive effect of vaccines, among all study participants, the number of vaccinations was significantly associated with the prevention of severe COVID-19, regardless of variant type. After stratified analyses by age, patients aged >= 80 remained a significant association for all variant types. On the other hand, the number of vaccinations had no association in Omicron BA.5 of patients aged 18-64. Conclusions Patients aged >= 80 had less reduction in risk of severe COVID-19 during the Omicron variant period, and a greater preventive effect of vaccines against severe COVID-19, compared to younger people. Our findings suggest that booster vaccination is effective and necessary for older people, especially aged >= 80.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Real-world evidence of safety and influence for lung cancer surgery under COVID-19 pandemic in Japan
    Kato, Taketo
    Katsuya, Ryotaro
    Okado, Shoji
    Sato, Keiyu
    Noritake, Osamu
    Nakanishi, Keita
    Noguchi, Misa
    Kadomatsu, Yuka
    Ueno, Harushi
    Ozeki, Naoki
    Nakamura, Shota
    Fukumoto, Koichi
    Chen-Yoshikawa, Toyofumi Fengshi
    [J]. JOURNAL OF THORACIC DISEASE, 2023, 15 (02) : 542 - +
  • [42] A Narrative Review COVID-19 in Solid-Organ Transplantation: Real-World Evidence From India
    Kute, Vivek B.
    Rela, Mohamed
    Abraham, Georgi
    Gulati, Sanjeev
    Bhalla, Anil K.
    Chauhan, Sanshriti
    Mishra, Vineet V.
    Meshram, Hari Shankar
    [J]. EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2022, 20 (08) : 32 - 42
  • [43] Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
    Birk, Navina K.
    Jain, Saniya
    Massoud, Louis
    Ramesh, Diya
    Monday, Lea
    Muma, Bruce
    Williams, Jonathan
    Alangaden, George
    Ramesh, Mayur
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (07):
  • [44] Treatment adherence in psoriatic patients during COVID-19 pandemic: Real-world data from a tertiary hospital in Greece
    Vakirlis, E.
    Bakirtzi, K.
    Papadimitriou, I.
    Vrani, F.
    Sideris, N.
    Lallas, A.
    Ioannides, D.
    Sotiriou, E.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (11) : E673 - E675
  • [45] Learning lessons from the COVID-19 pandemic for real-world evidence research in oncologydshared perspectives from international consortia
    Castelo-Branco, L.
    Lee, R.
    Brandao, M.
    Cortellini, A.
    Freitas, A.
    Garassino, M.
    Geukens, T.
    Grivas, P.
    Halabi, S.
    Oliveira, J.
    Pinato, D. J.
    Ribeiro, J.
    Peters, S.
    Pentheroudakis, G.
    Warner, J. L.
    Romano, E.
    [J]. ESMO OPEN, 2023, 8 (04)
  • [46] The Course of COVID-19 and Long COVID: Identifying Risk Factors among Patients Suffering from the Disease before and during the Omicron-Dominant Period
    Babicki, Mateusz
    Kolat, Damian
    Kaluzinska-Kolat, Zaneta
    Kapusta, Joanna
    Mastalerz-Migas, Agnieszka
    Jankowski, Piotr
    Chudzik, Michal
    [J]. PATHOGENS, 2024, 13 (03):
  • [47] Severe COVID-19 outcomes following vaccination in persons with multiple sclerosis: a real-world evidence study
    Geiger, C.
    Sheinson, D.
    Boudreau, D.
    Ng, C.
    Bajaj, P.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 654 - 655
  • [48] Central bank credibility during COVID-19: Evidence from Japan
    Christensen, Jens H. E.
    Spiegel, Mark M.
    [J]. JOURNAL OF INTERNATIONAL MONEY AND FINANCE, 2023, 131
  • [49] Firm Exit during the COVID-19 Pandemic: Evidence from Japan*
    Miyakawa, Daisuke
    Oikawa, Koki
    Ueda, Kozo
    [J]. JOURNAL OF THE JAPANESE AND INTERNATIONAL ECONOMIES, 2021, 59
  • [50] Covid-19 rural health inequities: insights from a real-world scenario
    Wagner, Teresa
    Ramirez, Clara
    Godoy, Brenda
    [J]. JOURNAL OF COMMUNICATION IN HEALTHCARE, 2022, 15 (01) : 22 - 26